SCHEMBL1637529

SCHEMBL1637529

COc1ccccc1-c1cccc(C(C)(O)c2cccc(-c3ccccc3)c2OCc2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.48
FFAR1 O14842 4/20 0.46
HTR7 P34969 3/20 0.44
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
PTGER1 P34995 6/20 0.42
PTGER4 P35408 5/20 0.42
PTGER3 P43115 5/20 0.42
PTGER2 P43116 5/20 0.42
ERN1 O75460 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
FYN P06241 1/20 0.40
BCHE P06276 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638726 0.93 PTPN5 (0.47) PTPN5FFAR1HTR7MGAMGAA
SCHEMBL1639404 0.93 MGAM (0.44) PTPN5FFAR1HTR7MGAMGAA
SCHEMBL1637791 0.91 PTPN5 (0.42) PTPN5FFAR1HTR7MGAMGAA
SCHEMBL1637767 0.89 PTPN5 (0.48) PTPN5FFAR1HTR7MGAMGAA
SCHEMBL27864181 0.87 MAOB (0.48) FFAR1MGAMGAASIMGAM2
SCHEMBL1637643 0.87 BCHE (0.43) MGAMGAASIMGAM2PTGER1
SCHEMBL1638857 0.87 MGAM (0.46) FFAR1MGAMGAASIMGAM2
SCHEMBL12646940 0.86 PTPN5 (0.45) PTPN5FFAR1HTR7L3MBTL1KDM4E
SCHEMBL1638148 0.83 PTPN5 (0.47) PTPN5FFAR1HTR7MGAMGAA
SCHEMBL27894243 0.83 MGAM (0.45) FFAR1MGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493932-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056423-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098429-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 PTPN5 4116/4885FFAR1 480/4885HTR7 3223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.